FDA Rehires Some Previously Laid-Off Staff Amid Concerns Over Medical Device Review Disruptions

Feb 25, 2025 10:30 CST Updated 10:30

Neuralink

Brain-Computer Interface System Developer

According toReuters, citing multiple sources familiar with the matter, reported that the FDA is moving to rehire some employees who were recently laid off, includingPersonnel involved in the review of Neuralink’s brain implant device projectPreviously, the Trump administration launched a large-scale layoff campaign, resulting in the departure of more than 1,000 employees from the U.S. Food and Drug Administration (FDA), including those in the Center for Devices and Radiological Health (CDRH). Earlier reports indicated that after Robert F. Kennedy Jr. was confirmed as Secretary of the Department of Health and Human Services (HHS), officials anticipated that HHS would terminate 5,200 probationary employees.

According to overseas reports, at least 11 CDRH employees have received invitations to return to work. However, the FDA has not yet issued any public comments regarding the rehiring process or the specific number of employees returning to their positions.

WhenThe Trump Administration, in order toImproving Government Efficiency and Reducing Expenditures, LaunchingThis Round of Massive Layoffs. When the Layoffs Reach the FDA,Raising Concerns About Delays in Medical Device Product ApprovalsScott Whitaker, CEO of the medical technology industry association AdvaMed, stated, “The layoffs could disrupt the FDA review process, and”Recalling these experts will help ensure an efficient regulatory system that supports medical innovation."

Although some former FDA employees have accepted reemployment offers, others remain on the sidelines. Reuters pointed out that multiple scientists who were previously dismissed had received excellent performance evaluations, yet their termination notices stated that their job performance was unsatisfactory.

Currently, the long-term impact of layoffs and rehiring initiatives on the regulatory framework remains uncertain. Industry stakeholders continue to closely monitor how personnel changes affect the approval cycles for medical devices and other innovative healthcare products.

Neuralink, Musk’s company, has not commented on the FDA’s recent layoffs and recalls. In 2023, the FDA had rejectedNeuralink Clinical Trials (Due to Safety Concerns), Later ApprovedClinical Studies on Neuralink Products.

According to Reuters, last week’s layoffs involved approximately 20 employees from the FDA’s Office of Neurological and Physical Medicine Devices, many of whom were involved in the review of Neuralink and other brain-computer interface (BCI) devices.

Since the Trump administration initiated large-scale layoffs, incidents of cutting into the “critical arteries” have occurred more than once. For instance, 300–400 employees responsible for nuclear safety at the U.S. Department of Energy were mistakenly laid off, prompting frantic efforts to recall them. In the future, the FDA may undergo multiple cycles of layoffs and recalls, especially given that even high-performing employees can be reclassified as underperformers.Subpar job performance. Layoffs driven solely by metrics will ultimately lead to chaos, potentially slowing the pace of medical device innovation (with a significant increase in overall innovation costs). China’s medical device industry may benefit from this, as few countries can compete with China in mature sectors. This could narrow the gap between China and the United States in the field of medical devices.